Samrat Pharma's Quarterly Financials Raise Concerns

This could be a cause for concern for investors.Net Profit Margin - Quarterly: The company's net profit margin has decreased from 182.43% in Jun 2023 to -131.15% in Sep 2023. This could be due to various factors such as increased expenses or decrease in sales. Interest - Quarterly: The company's interest expenses have increased by 40.91% in Sep 2023 compared to the previous quarter. This could indicate that the company has taken on more debt or has higher interest rates. Operating Profit Margin - Quarterly: The operating profit margin (excluding other income) has decreased from 257.14% in Jun 2023 to -71.43% in Sep 2023. This could be due to a decrease in sales or an increase in operating expenses. Net Sales - Quarterly: The net sales for the quarter ended Sep 2023 have shown a growth of 38.73% compared to the previous quarter. However, this growth is lower than the industry average of 50%. Standalone Net Profit - Quarterly: The standalone net profit for the quarter ended Sep 2023 has decreased by 131.15% compared to the previous quarter. This could be a cause for concern for investors. Despite these challenges, Samrat Pharma remains a key player in the pharma industry with a microcap size. The company has a strong track record and has shown resilience in the face of market fluctuations. It is important for investors to carefully analyze the financials and make informed decisions based on their risk appetite. MarketsMOJO has given a 'Sell' call for the stock, but it is always advisable to do your own research and consult with a financial advisor before making any investment decisions.